HUTCHMED (China) Limited (HCM)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

 300.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 352.00
  • 52 Week Low: 192.40
  • Currency: UK Pounds
  • Shares Issued: 871.47m
  • Volume: 87,739
  • Market Cap: £2,614.41m
  • RiskGrade: 226
  • Beta: 0.03

Latest ShareCast News

Hutchmed partner Takeda gets Japanese approval for Fruzaqla

By Josh White

Date: Tuesday 24 Sep 2024

(Sharecast News) - Hutchmed China announced on Tuesday that its partner Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to manufacture and market 'Fruzaqla', or fruquintinib, for the treatment of previously-treated metastatic colorectal cancer (CRC).

Hutchmed to present new and updated clinical trial data

By Josh White

Date: Monday 09 Sep 2024

(Sharecast News) - Hutchmed China has announced that it would present new and updated clinical trial data at two major oncology conferences - the 2024 World Conference on Lung Cancer (WCLC24) in San Diego, and the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona.

Hutchmed withdraws supplemental new drug application in China

By Josh White

Date: Friday 30 Aug 2024

(Sharecast News) - Hutchmed China has voluntarily withdrawn its supplemental new drug application (NDA) in China for the use of fruquintinib in combination with paclitaxel for second-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma, it announced on Friday.

Oncology revenue drives first-half growth for Hu... 31-Jul-2024 ShareCast
Hutchmed gets tazemetostat new drug application ... 04-Jul-2024 ShareCast
Hutchmed partner gets European approval for fruq... 24-Jun-2024 ShareCast
Hutchmed publishes positive sovleplenib trial re... 17-Jun-2024 ShareCast
Hutchmed China launches two cancer treatment tri... 14-May-2024 ShareCast
Hutchmed China to make several presentations at ... 05-Apr-2024 ShareCast
Hutchmed endometrial cancer treatment gets prior... 02-Apr-2024 ShareCast
Hutchmed cancer treatment indication accepted fo... 28-Mar-2024 ShareCast
Hutchmed partner Inmagene exercises options over... 02-Feb-2024 ShareCast
Hutchmed's 'Elunate' approved under new Hong Kon... 30-Jan-2024 ShareCast
Hutchmed application for thrombocytopenia treatm... 11-Jan-2024 ShareCast
Hutchmed completes trial enrolment, keeps drugs ... 13-Dec-2023 ShareCast
Hutchmed completes trial enrolment, keeps drugs ... 13-Dec-2023 ShareCast
Hutchmed confirms new drug application for fruqu... 29-Sep-2023 ShareCast
Director dealings: IPF non-exec picks up shares,... 14-Sep-2023 ShareCast
Hutchmed reports progress on two oncology fronts 12-Sep-2023 ShareCast
Hutchmed tumour therapy candidate gets breakthro... 29-Aug-2023 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HCM Market Data

Currency UK Pounds
Share Price 300.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 352.00
52 Week Low 192.40
Volume 87,739
Shares Issued 871.47m
Market Cap £2,614.41m
Beta 0.03
RiskGrade 226

HCM Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
77.04% below the market average77.04% below the market average77.04% below the market average77.04% below the market average77.04% below the market average
28% below the sector average28% below the sector average28% below the sector average28% below the sector average28% below the sector average
Price Trend
65.71% above the market average65.71% above the market average65.71% above the market average65.71% above the market average65.71% above the market average
83.67% above the sector average83.67% above the sector average83.67% above the sector average83.67% above the sector average83.67% above the sector average
Income Not Available
Growth
69.74% above the market average69.74% above the market average69.74% above the market average69.74% above the market average69.74% above the market average
88.24% above the sector average88.24% above the sector average88.24% above the sector average88.24% above the sector average88.24% above the sector average

HCM Dividends

No dividends found

Trades for 10-Oct-2024

Time Volume / Share Price
16:36 1,000 @ 300.00p
16:35 22,452 @ 300.00p
16:35 1,000 @ 300.00p
16:35 2,402 @ 300.00p
16:35 175 @ 300.00p

HCM Key Personnel

Chair Dan Eldar
CEO Weiguo Su

Top of Page